Literature DB >> 27637776

Treatment of Wound Healing Disorders of Radial Forearm Free Flap Donor Sites Using Cold Atmospheric Plasma: A Proof of Concept.

Stefan Hartwig1, Christian Doll2, Jan Oliver Voss2, Moritz Hertel3, Saskia Preissner4, Jan Dirk Raguse5.   

Abstract

PURPOSE: The treatment of wound healing disturbances of the radial forearm free flap donor site after reconstructive surgery is typically long and burdensome and often requires additional surgery. Cold atmospheric plasma is a promising approach to overcome these impairments. The aim of this proof of concept study was to evaluate the clinical outcome of plasma irradiation in patients with wound healing disorders with exposed brachial tendons of the radial forearm. PATIENTS AND METHODS: Four patients (mean age 64.2 years, range 44 to 80) who had undergone radial forearm free flap procedures and developed wound healing disturbance leading to exposed flexor tendons were included in the present prospective case series. In addition to routine wound care, all sites were irradiated with cold atmospheric plasma. The primary outcome variable was complete wound closure.
RESULTS: In all patients, complete wound repair in terms of the absence of tendon exposure was observed within a mean treatment time of 10.1 weeks (range 4.9 to 16). No undesirable side effects were observed, and no inflammation or infection occurred.
CONCLUSIONS: Cold atmospheric plasma could offer a reliable conservative treatment option for complicated wound healing disturbances. This was exemplarily shown in the case of radial forearm free flap donor site morbidity with exposed flexor tendons in the present study.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27637776     DOI: 10.1016/j.joms.2016.08.011

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  8 in total

1.  [Effect of a novel radio-frequency atmospheric-pressure glow discharge plasma jet treatment on crosslinking of dentin collagen].

Authors:  X R Ma; X M Zhu; J Li; D L Li; H P Li; J G Tan
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-02-18

2.  Anticancer Effects of Cold Atmospheric Plasma in Canine Osteosarcoma Cells.

Authors:  Jaehak Lee; Hyunjin Moon; Bonghye Ku; Keunho Lee; Cheol-Yong Hwang; Seung Joon Baek
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

3.  Cold Physical Plasma Modulates p53 and Mitogen-Activated Protein Kinase Signaling in Keratinocytes.

Authors:  Anke Schmidt; Sander Bekeschus; Katja Jarick; Sybille Hasse; Thomas von Woedtke; Kristian Wende
Journal:  Oxid Med Cell Longev       Date:  2019-01-13       Impact factor: 6.543

4.  Production of reactive species in alginate hydrogels for cold atmospheric plasma-based therapies.

Authors:  Cédric Labay; Inès Hamouda; Francesco Tampieri; Maria-Pau Ginebra; Cristina Canal
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

Review 5.  ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy.

Authors:  Angela Privat-Maldonado; Anke Schmidt; Abraham Lin; Klaus-Dieter Weltmann; Kristian Wende; Annemie Bogaerts; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2019-10-08       Impact factor: 6.543

Review 6.  Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity.

Authors:  Fatemeh Faramarzi; Parisa Zafari; Mina Alimohammadi; Mohammadreza Moonesi; Alireza Rafiei; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-12-24       Impact factor: 6.543

Review 7.  Comprehensive biomedical applications of low temperature plasmas.

Authors:  Simone Duarte; Beatriz H D Panariello
Journal:  Arch Biochem Biophys       Date:  2020-08-26       Impact factor: 4.013

8.  Anticancer Effects of Plasma-Activated Medium Produced by a Microwave-Excited Atmospheric Pressure Argon Plasma Jet.

Authors:  Ara Jo; Hea Min Joh; Tae Hun Chung; Jin Woong Chung
Journal:  Oxid Med Cell Longev       Date:  2020-07-30       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.